Facioscapulohumeral Muscular Dystrophies.

  title={Facioscapulohumeral Muscular Dystrophies.},
  author={Kathryn R. Wagner},
  journal={CONTINUUM: Lifelong Learning in Neurology},
  • Kathryn R. Wagner
  • Published 1 December 2019
  • Medicine, Biology
  • CONTINUUM: Lifelong Learning in Neurology
PURPOSE OF REVIEW Facioscapulohumeral muscular dystrophy (FSHD) is a common muscular dystrophy affecting both pediatric and adult patients. This article reviews the phenotype and pathophysiology of the disease as well as the recent efforts in clinical outcome measures and clinical trials. RECENT FINDINGS As the name implies, FSHD involves weakness of facial muscles, muscles that fix the scapula, and muscles overlying the humerus (biceps and triceps). The distinctive phenotype of FSHD occurs… 

Figures from this paper

Systemic manifestations and symptom burden of facioscapulohumeral muscular dystrophy in a referral cohort
The full spectrum of the clinical phenotype of facioscapulohumeral muscular dystrophy, beyond skeletal muscle weakness, remains poorly characterized and systemic manifestations and symptom burden in a large series of patients are described.
Circulating small RNA signatures differentiate accurately the subtypes of muscular dystrophies: small-RNA next-generation sequencing analytics and functional insights
The first genome-wide next-generation small RNA sequencing in serum samples of five different types of muscular dystrophy patients and healthy individuals is presented and provides a useful resource for future studies for the development of miRNA biomarkers in muscular dystrophies and for their involvement in the pathogenesis of the disorders.
Speech and swallowing characteristics in patients with facioscapulohumeral muscular dystrophy
FSHD patients presented mild dysarthria and dysphagia and Dysphagia was related to worsening disease severity, and frequent monitoring of these symptoms could be an important way to provide early rehabilitation and better quality of life.
Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials
Current and emerging F SHD outcome measures and the challenges that investigators may experience in applying such measures to FSHD clinical trial design and implementation are discussed.
Cross-sectional Neuromuscular Phenotyping Study of Patients With Arhinia With SMCHD1 Variants
The distinct dichotomy between FSHD2 and arhinia phenotypes despite an otherwise poised DUX4 locus implies the presence of novel disease-modifying factors that seem to operate as a switch, resulting in one phenotype and not the other.
Orofacial Muscle Weakening in Facioscapulohumeral Muscular Dystrophy (FSHD) Patients
Although FSHD patients exhibited a decrease in muscular activity related to the forehead, perioral, and periocular muscles the genotype–phenotype associations confirmed a weak to moderate non-significant correlation between repeat size and the severity of muscle weakness.
Cognitive profile of patients with facioscapulohumeral muscular dystrophy
Individuals with FSHD presented mild impairments in the performance of tasks that involve attention, planning, and long-term memory functions and those impairments were associated neither with the disease duration nor with its neurological severity.


Facioscapulohumeral muscular dystrophy in early childhood.
Infantile FSHD has been suggested to be a separate form of the disease, often accompanied by sensorineural hearing loss and retinal telangiectasia, but these findings suggest that early-onset F SHD is not a separate entity, but part of a wide clinical spectrum of FSHd.
FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit.
Facioscapulohumeral muscular dystrophy (FSHD) is a neuromuscular disorder characterized by progressive weakness of the facial, shoulder and upper arm muscles. The disease is associated with DNA
The 6-min walk distance in healthy subjects: reference standards from seven countries
New 6MWD standard curves are provided that could be useful in the care of adult patients with chronic diseases and caution must be taken when using existing predictive equations.
Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy
The 6MWT was reliable and demonstrated moderate to strong correlations with lower extremity strength, functional outcomes, and FSHD Clinical Score and was associated with other measures of F SHD disease severity.
Electrical impedance myography in facioscapulohumeral muscular dystrophy: A 1‐year follow‐up study
Although 50‐kHZ reactance correlated the strongest with clinical measures at baseline, the 50–211‐ kHZ phase ratio demonstrated lower within‐subject 12‐month variability, potentially offering sample size savings for FSHD clinical trial planning.
Aerobic training and postexercise protein in facioscapulohumeral muscular dystrophy
This randomized, controlled study showed that regular endurance training improves fitness, walking speed, and self-assessed health in patients with FSHD without causing muscle damage.